financetom
Business
financetom
/
Business
/
Olive Garden parent Darden to buy Chuy's in $605 million deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Olive Garden parent Darden to buy Chuy's in $605 million deal
Jul 17, 2024 2:55 PM

(Reuters) - Darden Restaurants ( DRI ), owner of the Olive Garden ( DRI ) chain, has agreed to buy full-service restaurant operator Chuy's Holdings in an all-cash deal which has an enterprise value of $605 million, the companies said on Wednesday.

The move would add 101 restaurants operated by Chuy's across 15 states in the U.S. to the iconic portfolio of brands owned by Darden such as LongHorn Steakhouse, Yard House, Ruth's Chris Steak House and Cheddar's Scratch Kitchen, among others.

Darden will acquire all of Chuy's outstanding shares for $37.50 per share in cash, which represents a 48.4% premium to the stock's closing on Wednesday.

Shares of Chuy's, which has a market capitalization of $436.78 million, according to LSEG data, surged over 47.4% to $37.24 in extended trading, while those of Darden dropped about 1%.

The deal, approved by the boards of both the companies, is expected to close in Darden's fiscal second quarter and is expected to be neutral to Darden's net earnings per share for its fiscal 2025.

Darden, which said it had sufficient liquidity to complete the all-cash deal, noted that the total acquisition and integration related expenses are expected to be between $50 million and $55 million, pre-tax.

Chuy's, which was founded over four decades ago, had total revenues of over $450 million in the twelve months ending March 31, 2024.

BofA Securities acted as the financial advisor to Darden, while Piper Sandler advised Chuy's.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Eli Lilly's Tirzepatide Injection No Longer in Shortage in US, FDA Says
Update: Eli Lilly's Tirzepatide Injection No Longer in Shortage in US, FDA Says
Oct 3, 2024
08:49 AM EDT, 10/03/2024 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response in the last two paragraphs.) Eli Lilly's ( LLY ) tirzepatide injection is no longer considered to be in short supply in the US, the US Food and Drug Administration said in a notice Wednesday. Tirzepatide injection had been in shortage since 2022 due to...
Murphy Oil Says $520.6 Million of Notes Tendered in Offers for Outstanding Debt
Murphy Oil Says $520.6 Million of Notes Tendered in Offers for Outstanding Debt
Oct 3, 2024
08:44 AM EDT, 10/03/2024 (MT Newswires) -- Murphy Oil ( MUR ) said Thursday that about $520.6 million of notes had been tendered in its tender offers to purchase for cash up to $600 million of some of its outstanding series of senior notes as of the early tender date of 5 pm ET on Wednesday. The offers are set...
Visa Launches Platform for Creation, Distribution of Digital Currencies
Visa Launches Platform for Creation, Distribution of Digital Currencies
Oct 3, 2024
08:46 AM EDT, 10/03/2024 (MT Newswires) -- Visa (V) said Thursday it has launched a tokenized asset platform to help financial firms issue and manage fiat-based tokens on blockchain networks. The platform is available to Visa's network of 15,000 partners on its developer platform. It will allow banks to mint and transfer fiat-backed digital currencies such as stablecoins. The company...
Spectral Medical Provides Updates on Tigris Trial; Completion Expected by Yearend
Spectral Medical Provides Updates on Tigris Trial; Completion Expected by Yearend
Oct 3, 2024
08:47 AM EDT, 10/03/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , a theranostic company advancing therapeutic options for sepsis and septic shock, on Thursday provided an update on its Tigris trial, a phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved